Science and publications

At ECO 2025 in Malaga, Yazen unveiled digital solutions and personalised strategies that are revolutionising obesity management and enhancing outcomes.

This 18-month real-world evaluation data analysis demonstrates that Yazen Health’s fully digital care model, integrating pharmacological treatment and lifestyle intervention can provide effective, sustainable results in a real-world setting.
‍

Summary

Patients achieved a weight reduction of 16.6%, accompanied by improvements in metabolic health markers including laboratory values, despite medication supply limitations and without using the maximum recommended dose of semaglutide. 70% remained in the program after 12 months. Weight loss outcomes were comparable to those observed in RCTs such as the STEP trials^1-2.

High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.
‍

Summary‍

This real-world analysis from Yazens first large scale operational quality follow-up, demonstrates almost 70% compliance with GLP-1 medications at 12 months, surpassing earlier studies that showed 20-50%^1-4. After 2 years*, 60% of patients were still in treatment.

The Yazen Model enables modern obesity treatment, integrating medical treatment, lifestyle intervention and social support. By now*, more than 30,000 patients have received treatment using this model.

Summary

The Yazen Model goes beyond traditional methods, providing patients with the tools to manage their disease, addressing medical and behavioural aspects, education and social support via a digital platform for accessible, continuous and effective weight loss and management.

A new survey by Yazen Health uncovers widespread misconceptions about obesity, with over one-third of Brits seeing it as a personal choice rather than a chronic disease. These findings highlight the urgent need for greater public education and medically-guided obesity care.